> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Meeting on Systemic Sclerosis Patient Perspectives
- URL: https://www.fdaweb.com/meeting-on-systemic-sclerosis-patient-perspectives/
- Published: 2020-09-29T12:00:00.000Z
- Updated: 2026-09-14T16:30:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147757

FDA has announced a 10/13 [virtual public meeting](https://u7061146.ct.sendgrid.net/ls/click?upn=4tNED-2FM8iDZJQyQ53jATUURzbOiTj4rjf8eQ-2FYEfOQ5THSul0bFGo4FhyR4b-2BPkN6tXfIb03jEQfD9nEWL3f9zp6qTLQ1TnQtywumfiKIWTfsqz1eo-2FJuT92HVTN-2FERDegvk6o8O-2BRg0ev6CJDN6sqUPjpwgJqqskgkR3ylXLf-2B3XRdeNaJ2ihR4-2BxFYM4u-2FB00Mg4xB-2F8VdXcgPbJ0AuCK1WJX7AQpx5ql0-2FWGEIYXABMAUQwi6K7aUakF4Yl9LbIuZfA7hNdbBPS3D0lINBKQ5aKYrMIsoFQuYcBYVU48fJ9WbyTn2Xf4zesMIA46JcgL1lq-2BUQw1jjBkT-2B1npKuPplegKalEFsiyl8jBKz7NhPpOrLA7UpTTlLDHoILbt01ON4Dgigh7OOzrcGOx4E1zoDeHOK-2F8Es5CjwbvAb7KGT7XWQcHWaJJ09FrQnEZ2pH2OtQwqRq4bIFLx85LQhqluFQP-2BEGw7Z1cR4yHQxbBxx2CC9a2-2F1bMJRoNCseixxS54mjbcAWvWP9rF5wOUzzpINB3x4f-2BpYByxbV-2FIXIdSIGJXE7e3kfJqKSvoy3bcw3jXVSYGhIRTuJvIVbYGX8Ms0JroSX2JUYK3427Yv9mbkbtQJXM1MP5ls2bfmQZtrbmd%5Ff0D7hj0BJ4b-2F7NuVqzPDs7FGiq8VLIwAX0sPSotqoLIZH-2BlHUpIN1Fpx16wXLzBItZQB-2B865N-2BRM-2FfR3UV9b-2B3x5yDeI-2BTg-2FGBCQMWf44N8QurlmdUM7U-2BEifY-2FRQFuV0nZaoILC3YwgqxnQWIWl7UzRGHaqKld3UdGatimW7UghbHAPL2StTcpCWbwxAWoJrvmzDV8j7qa1Pq25nu00JFbo5B714Q-2BmoimQwumtzt0RIzc7gFX7R-2Bp2QTSjWsZT9edpr23c-2BmBVj8i81hhEqhn8OUTIQ229bW8aPDZHO0FHnZeOLyvEeh-2FIus7LPbyVXVfSVo6UCoi6D3yxbMG3n-2BeimeDrTdYjHIWjSme-2BQvg-3D&ref=fdaweb.com) on Patient-Focused Drug Development (PFDD) for Systemic Sclerosis to obtain patients’ perspectives on disease impact on daily life and treatment approaches. [PFDD](https://u7061146.ct.sendgrid.net/ls/click?upn=4tNED-2FM8iDZJQyQ53jATUURzbOiTj4rjf8eQ-2FYEfOQ5THSul0bFGo4FhyR4b-2BPkN6tXfIb03jEQfD9nEWL3f97KHcaOOQ7u-2FaCjWJGOMNseOmO8gEl6SYs-2FDXcI1vvll98MimjFL8CeBXKlTveebYHU3ufmS6atjXDwIIroZjnSr-2FJ83MXgjqpmdj2vKjObZZYQjrEGJ4gksxJ2ZB1QslWT0n5xFIQqAGiYTuhXnDMfI1iHM3JjwFObvkp5ABvKEFPF4nTaCNUFTILDY3-2FbjgPUNnuekkp5ngLk2-2FBNUV7-2F02Y2xmKimvAkY3tSU19diYmOp43f-2FcRcIy6xRGqhS2OGoorolXuIZuBHndtNlgO-2BsJGYJSbHNuAea-2BMoXL3HZ0NMvTotoTPmhQmZgV1w2mM2mKVMXKqklv3uX-2FnpgD8x9TXXWmwFdpvis0ML8-2BUkiHgH3bS-2BCGsoDQPBOe5RLxxe-2FcuUc7gbdau8a-2FhXVVu0GdAJb2U-2F14MNJiEqUStEg3PI1nJxRP2jAbbCGGS0YphWkrJoqByysoK4SlTABIFLTPCgbaPs9Q4b-2BXebNXi-2BpNc3b%5Ff0D7hj0BJ4b-2F7NuVqzPDs7FGiq8VLIwAX0sPSotqoLIZH-2BlHUpIN1Fpx16wXLzBItZQB-2B865N-2BRM-2FfR3UV9b-2B3x5yDeI-2BTg-2FGBCQMWf44N8QurlmdUM7U-2BEifY-2FRQFuV0nZaoILC3YwgqxnQWIWl7UzRGHaqKld3UdGatimW7UghbHAPL2StTcpCWbwxAWoJ4ufDwFcRyjEfSzgmAU238Vys1mjf4jTGUmd5mCtgh-2FdYng2ESIav0nF2BgeYdVIhH8wN8irXeBS5kf-2FPROkB5-2FyD26R2-2Fi9-2FgCbQ5nVbO4psSIRHt-2BBoWfiS4L00UJTAUwgqMveQUoLWc9DZhHGnSt58juhuQZPgnIdOeFl6M-2Fo-3D&ref=fdaweb.com) is FDA’s systematic approach to “help ensure that patients’ experiences, perspectives, needs, and priorities are captured and meaningfully incorporated into drug development and evaluation,” the agency says. In addition to providing input at the public meeting, stakeholders can provide their perspectives through the [public docket.](https://www.regulations.gov/document?D=FDA-2020-N-1934-0001&ref=fdaweb.com)